fashion -WSS

fashion

author：hotspot 2025-09-06 03:39:51 - browse：94621

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: The latest on Moderna, Apellis, and Merck

Wikipedia

WSS

Lawsuit highlights wrinkle for disputes over surprise medical bills

Virtual care provider acquires bankrupt Pear's prescription apps

Flu, Covid vaccination rates decline, new survey data show

Medicare innovation center doesn’t save money, experts say

SNAP should offer more nutrition education

Drinking less cuts risk of oral cavity, esophageal cancer: Report

leisure time

fashion

entertainment

Affirmative action in medical school literally saved lives

Bristol Myers buys into radiopharmaceuticals with RayzeBio

In age of alternative facts, a scholarly course on calling out crap

What STAT readers think about the FDA and patient advocacy

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

SEC charges former device maker CEO with $41 million fraud

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The United States is paying nearly triple for new Covid vaccines

Supreme Court strikes down use of affirmative action

Setback for rare diseases as Taysha Gene Therapies pulls back

leisure time

CRISPR gene editing developments we’re watching in 2024

Prime Medicine, Myeloid Therapeutics clash over genome

CRISPR gene editing developments we’re watching in 2024

Hospitals owned by private equity see complications spike 25%

What STAT readers think about the FDA and patient advocacy

In Spain, a hospital brews its own CAR

knowledge

Wikipedia

hotspot

Wikipedia